trending Market Intelligence /marketintelligence/en/news-insights/trending/9T4aYSGRORVnGqpVLO7HRw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Danaher to sell 5 businesses to win EU approval for $21.4B GE Healthcare buy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Danaher to sell 5 businesses to win EU approval for $21.4B GE Healthcare buy

Danaher Corp.'s $21.4 billion acquisition of General Electric Co.'s biopharmaceutical business has been approved by the European Commission after Danaher agreed to divest five of its businesses.

Washington, D.C.-based Danaher in February announced plans to buy the industrial giant's biopharma business, which is part of the GE Healthcare Inc. unit that provides equipment and software used in biopharmaceutical research and development.

Both companies manufacture products and services used in the bioprocessing industries including single-use technology products. The companies are also competitors in molecular characterization, microscopy, high-content screening and laboratory filtration.

In order to close the deal, Danaher has agreed to sell five of its businesses. The commission raised concerns that the deal would reduce competition and result in higher prices, less innovation and increase the risk of discontinuation of certain products.

Danaher will offload the MolDev FortéBio molecular characterization business, Pall Biotech SoloHill microcarriers and particle validation standards business, the Pall Biotech chromatography resins business, the Pall Biotech chromatography hardware business, and the Pall Biotech Single-Use Tangential Flow Filtration systems and stainless-steel Hollow-Fibre Tangential Flow Filtration systems business.

The final sale of the businesses is subject to the commission's approval.